Q5103 HCPCS Level II code: Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg
Q5103 is the HCPCS code for “Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
Q5103Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg
Short description: Injection, inflectra
HCPCS · United States
Notes for Q5103
As CMS prints them, with any note Q5103 takes from the headings above it.
Note
- CMS processing note 0187: PUB. 100-4, CHAPTER 17.
Medicare details
The indicators CMS publishes with Q5103 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Added
- Apr 1, 2018
Where Q5103 sits
- 1Q codesTemporary codes
- 2Active code Q5103Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code Q5103 mean?
Q5103 is the HCPCS code for “Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover Q5103?
CMS lists Q5103’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside Q5103
All Q codesQ5010Hospice home care provided in a hospice facilityQ5098Injection, ustekinumab-srlf (imuldosa), biosimilar, 1 mgQ5099Injection, ustekinumab-stba (steqeyma), biosimilar, 1 mgQ5100Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mgQ5101Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgramQ5102Injection, infliximab, biosimilar, 10 mgQ5104Injection, infliximab-abda, biosimilar, (renflexis), 10 mgQ5105Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 unitsQ5106Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 unitsQ5107Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mgQ5108Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mgQ5109Injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg